gene_symbol
FCGR2A
hgnc_id
HGNC:3616
binding_type
receptor ligand recognition
cytotoxicity
NO
cytotoxicity_type
INDIRECT
cytotoxicity_mechanism
Enoblituzumab binds B7-H3 on tumor cells; its Fc engages FcγRIIa (CD32A) on effector cells (e.g., macrophages) to mediate ADCC/ADCP against B7‑H3+ cells. CD32A+ cells are not killed; they mediate killing.
enzyme_product
Off
epitope
Off
variant
Off
isoform
Off
hla_specific
Off
gated
Off
other_modifier
Fc-mediated engagement for ADCP (macrophages)
trial_id_tar_ref
drug_id_tar_ref
disease_id_tar_ref
nct_id_tar_ref
NCT06014255
disease_id_num_tar_ref
2738
drug_id_num_tar_ref
7289